128 related articles for article (PubMed ID: 36638354)
1. How we treat advanced biliary tract cancers in the second-line setting.
Ellis H; Raghavan S; Wolpin BM; Cleary JM
Clin Adv Hematol Oncol; 2023 Jan; 21(1):35-42. PubMed ID: 36638354
[No Abstract] [Full Text] [Related]
2. Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers.
Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
J Oncol Pharm Pract; 2023 Jun; 29(4):1027. PubMed ID: 36972505
[No Abstract] [Full Text] [Related]
3. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Pramanik R; Sharma A; Kumar A
Lancet Oncol; 2021 Jul; 22(7):e287. PubMed ID: 34197750
[No Abstract] [Full Text] [Related]
4. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Foo T; Kichenadasse G; Roy A; Karapetis CS
Lancet Oncol; 2021 Jul; 22(7):e286. PubMed ID: 34197749
[No Abstract] [Full Text] [Related]
5. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Brandi G; Frega G; Rizzo A
Lancet Oncol; 2021 Jul; 22(7):e285. PubMed ID: 34197748
[No Abstract] [Full Text] [Related]
6. Second-line FOLFOX chemotherapy for advanced biliary tract cancer.
Wei F
Lancet Oncol; 2021 Jul; 22(7):e284. PubMed ID: 34197747
[No Abstract] [Full Text] [Related]
7. Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 Jul; 22(7):e288-e289. PubMed ID: 34197751
[No Abstract] [Full Text] [Related]
8. Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?
Rizzo A; Cusmai A; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):201-203. PubMed ID: 35220859
[No Abstract] [Full Text] [Related]
9. Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer-a commentary from the Young International Society of Geriatric Oncology.
Liposits G; Arora SP; Battisti NML; Soto-Perez-de-Celis E; Loh KP; Williams GR
Ann Oncol; 2023 Jun; 34(6):555-556. PubMed ID: 36813114
[No Abstract] [Full Text] [Related]
10. [Not Available].
Delaye M; Lièvre A; Neuzillet C
Bull Cancer; 2022 Nov; 109(11S):11S11-11S20. PubMed ID: 36535758
[TBL] [Abstract][Full Text] [Related]
11. Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
Li YC; Li KS; Liu ZL; Tang YC; Hu XQ; Li XY; Shi AD; Zhao LM; Shu LZ; Lian S; Yan ZD; Huang SH; Sheng GL; Song Y; Liu YJ; Huan F; Zhang MH; Zhang ZL
Front Immunol; 2022; 13():1049812. PubMed ID: 36389727
[TBL] [Abstract][Full Text] [Related]
12. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
Ikeda M; Ioka T; Fukutomi A; Morizane C; Kasuga A; Takahashi H; Todaka A; Okusaka T; Creasy CL; Gorman S; Felitsky DJ; Kobayashi M; Zhang F; Furuse J
Cancer Sci; 2018 Jan; 109(1):215-224. PubMed ID: 29121415
[TBL] [Abstract][Full Text] [Related]
15. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
16. Equipoise, drug development, and biliary cancer.
Lee TY; Bates SE; Abou-Alfa GK
Cancer; 2022 Mar; 128(5):944-949. PubMed ID: 34817855
[No Abstract] [Full Text] [Related]
17. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
19. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
Ricci AD; Rizzo A
Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
[TBL] [Abstract][Full Text] [Related]
20. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002.
Goodman MT; Yamamoto J
Cancer Causes Control; 2007 May; 18(4):415-22. PubMed ID: 17264972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
